CORONOVIRUS INFECTION (COVID-19) IN PEDIATRIC PRACTICE
- Authors
-
-
Abdullaeva Mukhlisa Masrurovna
Assistant of the Department of Propaedeutics of Childhood Diseases of Tashkent Medical Academy of the Republic of Uzbekistan
-
- Abstract
-
COVID-19 has impacted many children, severe disease is rare and most recover with supportive care. Manifestations are diverse and often nonrespiratory. Adolescents/children with medical comorbidities are at risk for severe respiratory compromise. The most serious manifestation in previously healthy children is a delayed multisystem inflammatory syndrome with cardiac compromise in severe cases. Anti–SARS-CoV-2 monoclonal antibodies are available for adolescents at risk of progression and not hospitalized. Therapeutic options for severe respiratory disease with hypoxia include remdesivir and glucocorticoids. Therapies for multisystem inflammatory syndrome in children include intravenous immunoglobulin and glucocorticoids.
- References
-
American Academy of Pediatrics Children and COVID-19: state-level data report. 2021. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/ Available at: Accessed November 6, 2021.
2.Pray I.W., Gibbons-Burgener S.N., Rosenberg A.Z., et al. COVID-19 outbreak at an overnight summer school retreat - Wisconsin, July-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(43):1600–1604.
3.Falk A., Benda A., Falk P., et al. COVID-19 cases and transmission in 17 K-12 schools - Wood County, Wisconsin, August 31-November 29, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(4):136–140.
4.Viner R.M., Mytton O.T., Bonell C., et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021;175(2):143–156. doi: 10.1001/jamapediatrics.2020.4573.
5.Hershow R.B., Wu K., Lewis N.M., et al. Low SARS-CoV-2 transmission in elementary schools - Salt Lake County, Utah, December 3, 2020-January 31, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(12):442–448.
6.Bunyavanich S., Do A., Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323(23):2427–2429.
7.Pierce C.A., Sy S., Galen B., et al. Natural mucosal barriers and COVID-19 in children. JCI Insight. 2021;6(9):e1486911.
8.Poston D., Weisblum Y., Wise H., et al. Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection. Clin Infect Dis. 2020
9.Steinman J.B., Lum F.M., Ho P.P., et al. Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. Proc Natl Acad Sci U S A. 2020;117(40):24620–24626.
10.Kim L., Whitaker M., O'Halloran A., et al. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1081–1088.
11.Goyal M.K., Simpson J.N., Boyle M.D., et al. Racial and/or ethnic and socioeconomic disparities of SARS-CoV-2 infection among children. Pediatrics. 2020;146(4)
12.Zachariah P., Johnson C.L., Halabi K.C., et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children's hospital in New York City, New York. JAMA Pediatr. 2020:e202430. doi: 10.1001/jamapediatrics.2020.2430.
13.DeBiasi R.L., Song X., Delaney M., et al. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. J Pediatr. 2020 doi: 10.1016/j.jpeds.2020.05.007.
14.Center for Disease Control and Prevention COVID-19 Pandemic Planning Scenarios. 2021. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html Available at: Accessed May 25, 2021.
15.Davies N.G., Klepac P., Liu Y., et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205–1211.
16.Hains D.S., Schwaderer A.L., Carroll A.E., et al. Asymptomatic seroconversion of immunoglobulins to SARS-CoV-2 in a pediatric dialysis unit. JAMA. 2020;323(23):2424–2425.
17.Fernandes D.M., Oliveira C.R., Guerguis S., et al. SARS-CoV-2 clinical syndromes and predictors of disease severity in hospitalized children and youth. J Pediatr. 2020
18.Zachariah P., Halabi K.C., Johnson C.L., et al. Symptomatic infants have higher nasopharyngeal SARS-CoV-2 viral loads but less severe disease than older children. Clin Infect Dis. 2020;71(16):2305–2306.
19.Paret M., Lighter J., Pellett Madan R., et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in febrile infants without respiratory distress. Clin Infect Dis. 2020;71(16):2243–2245.
20.Feldstein L.R., Rose E.B., Horwitz S.M., et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334–346.
21.Dufort E.M., Koumans E.H., Chow E.J., et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347–358.
22.Belay E.D., Abrams J., Oster M.E., et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic. JAMA Pediatr. 2021
23.Center for Disease Control and Prevention .A. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). 2021.
24.Godfred-Cato S., Bryant B., Leung J., et al. COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1074–1080. doi: 10.15585/mmwr.mm6932e2.
25.Lee P.Y., Day-Lewis M., Henderson L.A., et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. 2020;130(11):5942–5950.
26.Noval Rivas M., Porritt R.A., Cheng M.H., et al. COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): a novel disease that mimics toxic shock syndrome-the superantigen hypothesis. J Allergy Clin Immunol. 2021;147(1):57–59.
27.Vella L.A., Giles J.R., Baxter A.E., et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Sci Immunol. 2021;6(57) doi: 10.1126/sciimmunol.abf7570. eabf7570.47.
28.Rostad C.A., Chahroudi A., Mantus G., et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C) Pediatrics. 2020;146(6)
29.Swann O.V., Holden K.A., Turtle L., et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020;370:m3249.
30.Shekerdemian L.S., Mahmood N.R., Wolfe K.K., et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to us and Canadian pediatric intensive care units. JAMA Pediatr. 2020;174(9):868–873.
31.Leidman E., Duca L.M., Omura J.D., et al. COVID-19 trends among persons aged 0-24 years - United States, March 1-December 12, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(3):88–94.
32.Delahoy M.J., Ujamaa D., Whitaker M., et al. Hospitalizations associated with COVID-19 among children and adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(36):1255–1260.
33.Viner R.M., Ward J.L., Hudson L.D., et al. Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents. Arch Dis Child. 2020
34.Loron G., Tromeur T., Venot P., et al. COVID-19 associated with life-threatening APNEA in an infant born preterm: a case report. Front Pediatr. 2020;8:568.
35.Derespina K.R., Kaushik S., Plichta A., et al. Clinical manifestations and outcomes of critically ill children and adolescents with coronavirus disease 2019 in New York City. J Pediatr. 2020
36.Duarte-Neto A.N., Caldini E.G., Gomes-Gouvea M.S., et al. An autopsy study of the spectrum of severe COVID-19 in children: from SARS to different phenotypes of MIS-C. EClinicalMedicine. 2021;35:100850.
37.Van Brusselen D., De Troeyer K., Ter Haar E., et al. Bronchiolitis in COVID-19 times: a nearly absent disease? Eur J Pediatr. 2021;180(6):1969–1973.
38.Sheehan W.J., Patel S.J., Margolis R.H.F., et al. Pediatric asthma exacerbations during the COVID-19 pandemic: absence of the typical fall seasonal spike in Washington, DC. J Allergy Clin Immunol Pract. 2021;9(5):2073–2076.
39.Yonker L.M., Gilboa T., Ogata A.F., et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J Clin Invest. 2021
40.Giovanni J.E., Hrapcak S., Melgar M., et al. Global reports of intussusception in infants with SARS-CoV-2 infection. Pediatr Infect Dis J. 2021;40(1):e35–e36.
41.Miller J., Cantor A., Zachariah P., et al. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children that is related to coronavirus disease 2019: a single center experience of 44 cases. Gastroenterology. 2020;159(4):1571–1574.e1572.
42.Dolhnikoff M., Ferreira Ferranti J., de Almeida Monteiro R.A., et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolescent Health. 2020;4(10):790–794.
43.Valverde I., Singh Y., Sanchez-de-Toledo J., et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. 2021;143(1):21–32.
44.LaRovere K.L., Riggs B.J., Poussaint T.Y., et al. neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol. 2021;78(5):536–547.
